Literature DB >> 8387398

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Y Pommier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8387398     DOI： 10.1007/bf00685611

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  92 in total

Review 1.  Recent studies of DNA topoisomerases.

Authors:  J C Wang
Journal:  Biochim Biophys Acta       Date:  1987-06-06

2.  Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination.

Authors:  P Bullock; J J Champoux; M Botchan
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

3.  Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  J Mol Biol       Date:  1991-12-20       Impact factor: 5.469

4.  Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.

Authors:  R Ganapathi; D Grabowski; J Ford; C Heiss; D Kerrigan; Y Pommier
Journal:  Cancer Commun       Date:  1989

5.  Role of DNA topoisomerase I in the transcription of supercoiled rRNA gene.

Authors:  L C Garg; S DiAngelo; S T Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe.

Authors:  T Uemura; H Ohkura; Y Adachi; K Morino; K Shiozaki; M Yanagida
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

7.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.

Authors:  M Berrios; N Osheroff; P A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Acidic phospholipids directly inhibit DNA binding of mammalian DNA topoisomerase I.

Authors:  H Tamura; Y Ikegami; K Ono; K Sekimizu; T Andoh
Journal:  FEBS Lett       Date:  1990-02-12       Impact factor: 4.124

9.  Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.

Authors:  J Y Chang; F S Han; S Y Liu; Z Q Wang; K H Lee; Y C Cheng
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

10.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205
View more
  37 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors.

Authors:  Natisha Magan; Agnieszka P Szremska; Richard J Isaacs; Kathryn M Stowell
Journal:  Biochem J       Date:  2003-09-15       Impact factor: 3.857

3.  A multiscale dynamic model of DNA supercoil relaxation by topoisomerase IB.

Authors:  Todd D Lillian; Maryna Taranova; Jeff Wereszczynski; Ioan Andricioaei; N C Perkins
Journal:  Biophys J       Date:  2011-04-20       Impact factor: 4.033

4.  p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.

Authors:  M I Sandri; R J Isaacs; W M Ongkeko; A L Harris; I D Hickson; M Broggini; F Vikhanskaya
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

Review 5.  Cellular senescence and cancer chemotherapy resistance.

Authors:  Ryan R Gordon; Peter S Nelson
Journal:  Drug Resist Updat       Date:  2012-02-23       Impact factor: 18.500

6.  Topoisomerase function during replication-independent chromatin assembly in yeast.

Authors:  W I Garinther; M C Schultz
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 7.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Authors:  Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

9.  Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.

Authors:  Nunzio Antonio Cacciola; Romina Sepe; Floriana Forzati; Antonella Federico; Simona Pellecchia; Umberto Malapelle; Alfonso De Stefano; Danilo Rocco; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-28       Impact factor: 3.000

10.  Gene expression profile of cervical and skin tissues from human papillomavirus type 16 E6 transgenic mice.

Authors:  D Mendoza-Villanueva; J Diaz-Chavez; L Uribe-Figueroa; C Rangel-Escareão; A Hidalgo-Miranda; S March-Mifsut; G Jimenez-Sanchez; Pf Lambert; P Gariglio
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.